We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.13B
AUM Growth
+$681M
Cap. Flow
-$365M
Cap. Flow %
-11.64%
Top 10 Hldgs %
43.55%
Holding
107
New
15
Increased
23
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
AHCO icon
AdaptHealth
AHCO
+$171M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$55.9M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$37.8M
4
KRRO icon
Korro Bio
KRRO
+$22.1M
5
ARDX icon
Ardelyx
ARDX
+$21.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$57.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$52.7M
3
CHRS icon
Coherus Oncology
CHRS
+$31.2M
4
IMMU
Immunomedics Inc
IMMU
+$26.3M
5
DFBHU
DFB Healthcare Acquisitions Corp. Unit
DFBHU
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.62%
2 Financials 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AHCO icon
1
AdaptHealth
AHCO
$1.49B
$189M 6.03%
+17,199,888
New +$171M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$172M 5.48%
4,742,311
-1,720,323
-27% -$52.7M
VTRS icon
3
Viatris
VTRS
$20.1B
$164M 5.23%
8,151,754
+497,689
+7% +$9.26M
ORTX
4
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$122M 3.89%
886,225
-6,135
-0.7% -$746K
QTTB icon
5
Q32 Bio
QTTB
$255M
$109M 3.46%
291,424
-28,596
-9% -$8.19M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.31B
$98.5M 3.14%
4,289,291
+1,700,000
+66% +$37.8M
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$7.25B
$84.6M 2.7%
3,448,912
– –
TNDM icon
8
Tandem Diabetes Care
TNDM
$1.17B
$81.2M 2.59%
1,361,345
+907,011
+200% +$55.9M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$72.6M 2.32%
1,369,625
+64,451
+5% +$2.94M
RARX
10
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$71.3M 2.28%
1,519,718
-208,301
-12% -$9.21M
CNC icon
11
Centene
CNC
$32.8B
$69.7M 2.22%
1,108,400
+388,000
+54% +$21M
XENT
12
DELISTED
Intersect ENT, Inc
XENT
$69.6M 2.22%
2,797,033
-311,971
-10% -$6.32M
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$57.5M 1.83%
789,000
-192,430
-20% -$11.7M
ARDX icon
14
Ardelyx
ARDX
$1.28B
$52.6M 1.68%
7,004,253
+3,603,843
+106% +$21.9M
BKD icon
15
Brookdale Senior Living
BKD
$3.58B
$52.5M 1.68%
7,223,419
+16,180
+0.2% +$120K
SILK
16
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$51.7M 1.65%
1,279,480
+300,000
+31% +$10.5M
DBVT
17
DBV Technologies
DBVT
$870M
$50.9M 1.62%
475,600
+155,478
+49% +$12.4M
RCKT icon
18
Rocket Pharmaceuticals
RCKT
$376M
$49.3M 1.57%
2,164,471
+390,533
+22% +$6.52M
VCEL icon
19
Vericel Corp
VCEL
$2.38B
$47.8M 1.53%
2,747,563
+666,563
+32% +$11.3M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$45.3M 1.44%
564,914
+187,714
+50% +$14.1M
ARVN icon
21
Arvinas
ARVN
$517M
$44.7M 1.43%
1,088,234
+167,000
+18% +$4.89M
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
$42.8M 1.37%
1,772,255
-2,796,569
-61% -$57.9M
FATE icon
23
Fate Therapeutics
FATE
$324M
$39.2M 1.25%
2,002,605
+49,708
+3% +$789K
SIEN
24
DELISTED
Sientra, Inc.
SIEN
$37.8M 1.21%
422,768
+9,021
+2% +$680K
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$36.5M 1.16%
1,722,618
-1,491,382
-46% -$26.3M
1
2 3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2019 Portfolio in Review

As of Q4 2019, Deerfield Management held 107 positions worth $3.13B, up 28% from $2.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $365M in Q4 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Coherus Oncology, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 71% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in AdaptHealth worth $189M.

  • Deerfield Management's largest Q4 2019 buy was AdaptHealth: 17,199,888 shares worth $189M.
  • Deerfield Management added most to Tandem Diabetes Care in Q4 2019, an estimated $55.9M increase.
  • Deerfield Management's biggest Q4 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $57.9M.
  • Deerfield Management fully exited Coherus Oncology in Q4 2019, selling an estimated $31.2M.
  • Deerfield Management's ten largest holdings make up 44% of its $3.13B portfolio in Q4 2019.
  • Deerfield Management opened 15 new positions and closed 31 in Q4 2019.
  • Deerfield Management's portfolio value rose 28% quarter-over-quarter to $3.13B.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.